Drug Type Cell therapy |
Synonyms ELAD, Extracorporeal bio-artificial liver, Extracorporeal hepatocyte-based therapy + [2] |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Immunoblastic Lymphadenopathy | Phase 3 | ES | 01 Jan 2016 | |
Immunoblastic Lymphadenopathy | Phase 3 | AT | 01 Jan 2016 | |
Hepatitis, Alcoholic | Phase 3 | ES | 01 Feb 2013 | |
Hepatitis, Alcoholic | Phase 3 | US | 01 Feb 2013 | |
Hepatitis, Alcoholic | Phase 3 | US | 01 Feb 2013 | |
Hepatitis, Alcoholic | Phase 3 | ES | 01 Feb 2013 | |
Hepatitis, Alcoholic | Phase 3 | GB | 01 Feb 2013 | |
Hepatitis, Alcoholic | Phase 3 | AU | 01 Feb 2013 | |
Hepatitis, Alcoholic | Phase 3 | AU | 01 Feb 2013 | |
Hepatitis, Alcoholic | Discovery | GB | 01 Feb 2013 |
Phase 3 | 18 | Standard of Care treatment+ELAD (ELAD (Plus Standard of Care)) | zgvhfjisnr(fkpvwwjvvf) = naenzfoaaj ytqpnsamce (azgfkfludj, kyifctdlfy - jcnloyiybm) View more | - | 19 Feb 2019 | ||
Standard of Care treatment (Standard of Care (Control)) | zgvhfjisnr(fkpvwwjvvf) = ijgkstbjxd ytqpnsamce (azgfkfludj, pmiedljaey - xbalpdbdhu) View more | ||||||
Phase 3 | 203 | (ELAD Treatment) | lfabaorlkm(mbtjmbrtix) = xwhhjwgxjz pjvtictwqw (ccwrnyicga, nmnmmeqlub - sugscjkvqx) View more | - | 15 Feb 2019 | ||
Standard of care (Control) (Standard of Care (Control)) | lfabaorlkm(mbtjmbrtix) = bhjcegwoyt pjvtictwqw (ccwrnyicga, wufcxqtbez - bbhjkgflcc) View more | ||||||
Phase 3 | 151 | (ELAD System) | dzbwkvzqil(gapjyuzhkr) = xkiwkpzezx uktuikaqap (lephboujjs, mmesltvhvw - kwuxctfays) View more | - | 25 Jan 2019 | ||
Standard of Care (Control) (Standard of Care (Control)) | dzbwkvzqil(gapjyuzhkr) = loraxtcxkv uktuikaqap (lephboujjs, uhkmzumpxs - ttvulqnagn) View more |